An Open Label Study to Examine the Effects of DAS181 Administered by Dry Powder Inhaler (DPI) or Nebulized Formulation in Immunocompromised Subjects With Parainfluenza (PIV) Infection

Completed · Phase 2

Conditions studied: Parainfluenza

In brief

This protocol will seek to enroll up to 60 immunocompromised subjects diagnosed with parainfluenza infection. All subjects will have additional PK and Immunogenicity blood samples collected.

Key facts

Study ID

NCT01924793

Run by

Ansun Biopharma, Inc.

People needed

23

Starts

2013-08-01

Expected to finish

2017-05-01

Last updated by the study team

2017-07-19

Who can join

Age: 12 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age ≥12 years
• Able to provide informed consent or child assent with parental consent
• Immunocompromised, as defined by one of the following:
• Allogeneic hematopoietic cell transplantation (HCT)
• Lung or lung-heart transplantation
• Patients treated with chemotherapy for hematologic malignancies or autologous HCT
• Confirmed Parainfluenza virus by nasopharyngeal swab or tracheal aspirate for one of the following:
• Respiratory virus panel
• DFA
• Qualitative/quantitative RT-PCR test for parainfluenza virus performed at the local laboratory (a confirmatory PCR test will be done at the central lab but is not required to start the patient on study).
• Female subjects of child-bearing potential who are capable of conception must be:
• post-menopausal (one year or greater without menses), surgically incapable of childbearing, or practicing two effective methods of birth control. Acceptable methods include intrauterine device, spermicide, barrier, male partner surgical sterilization and hormonal contraception. A female subject must agree to practice two acceptable methods of birth control during the 28 day study period. Abstinence is not an acceptable method of contraception. All reproductive female subjects must have a negative serum pregnancy test during the screening visit.
• Male subjects must agree to use medically accepted form of contraception during the 28 day study period.

You may not qualify if…

• Psychiatric or cognitive illness or recreational drug/alcohol use that, in the opinion of the principal investigator, would affect patient safety and/or compliance.
• Any significant finding in the patient's medical history or physical examination that, in the opinion of the investigator, would affect patient safety, ability to use the dry powder inhaler or compliance with the dosing schedule.
• Subjects currently treated with oral, aerosolized or IV ribavirin
• Subjects taking any investigational drug used to research or treat PIV

Where it is running

• City of Hope — Duarte, California, United States
• Children's Hospital of Orange County — Orange, California, United States
• Stanford University Medical Center — Palo Alto, California, United States
• University of Chicago — Chicago, Illinois, United States
• Indiana Blood and Marrow Transplantation — Indianapolis, Indiana, United States
• University of Kansas Cancer Center — Kansas City, Kansas, United States
• John Hopkins University School of Medicine — Baltimore, Maryland, United States
• Brigham & Women's Hospital — Boston, Massachusetts, United States
• University of Minnesota, School of Medicine — Minneapolis, Minnesota, United States
• Washington University School of Medicine — St Louis, Missouri, United States
• Hackensack University Medical Center — Hackensack, New Jersey, United States
• Weill Cornell Medical College/New York Presbyterian Hospital — New York, New York, United States
• Weill Cornell Medical College-Peds — New York, New York, United States
• Duke University — Durham, North Carolina, United States
• The Ohio State University Wexner Medical Center — Columbus, Ohio, United States
• University of Oklahoma — Oklahoma City, Oklahoma, United States
• Hospital of the University of Pennsylvania — Philadelphia, Pennsylvania, United States
• University of Pittsburgh Medical Center — Pittsburgh, Pennsylvania, United States
• Medical University of South Carolina — Charleston, South Carolina, United States
• St. Jude Children's Research Hospital — Memphis, Tennessee, United States
• The University of Texas MD Anderson Cancer Center — Houston, Texas, United States
• Seattle Children's Hospital — Seattle, Washington, United States
• Fred Hutchinson Cencer Research Center — Seattle, Washington, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.